

Product datasheet for **TL320615**

MAP4K4 Human shRNA Plasmid Kit (Locus ID 9448)

Product data:

Product Type:	shRNA Plasmids
Product Name:	MAP4K4 Human shRNA Plasmid Kit (Locus ID 9448)
Locus ID:	9448
Synonyms:	FLH21957; HEL-S-31; HGK; MEKKK4; NIK
Vector:	pGFP-C-shLenti (TR30023)
E. coli Selection:	Chloramphenicol (34 ug/ml)
Mammalian Cell Selection:	Puromycin
Format:	Lentiviral plasmids
Components:	MAP4K4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 9448). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq:	NM_001242559 , NM_001242560 , NM_004834 , NM_145686 , NM_145687 , NM_145686.1 , NM_145686.2 , NM_145686.3 , NM_004834.1 , NM_004834.2 , NM_004834.3 , NM_004834.4 , NM_145687.1 , NM_145687.2 , NM_145687.3 , NM_001242560.1 , NM_001242559.1 , BC010909 , BC040077 , BC045694 , BC051791 , BC054038 , BC064691 , BC065036 , BC156089 , BC156887 , NM_001242559.2 , NM_004834.5 , NM_001242560.2 , NM_145687.4
UniProt ID:	O95819
Summary:	The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase has been shown to specifically activate MAPK8/JNK. The activation of MAPK8 by this kinase is found to be inhibited by the dominant-negative mutants of MAP3K7/TAK1, MAP2K4/MKK4, and MAP2K7/MKK7, which suggests that this kinase may function through the MAP3K7-MAP2K4-MAP2K7 kinase cascade, and mediate the TNF-alpha signaling pathway. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).